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INTRODUCTION
Since the recognition of acquired immune deficiency syndrome 
(AIDS), which gave rise to pneumocystis pneumonia and Kaposi’s 
sarcoma in young homosexual men across many cities, including 
Los Angeles, in the US in 1980 to 1981, the pathogenic organism 
have been isolated from patients with this syndrome and named 
lymphadenopathy-associated virus in 1983 [1-3]. Researchers 
named this immunodeficiency disorder as AIDS, which is caused 
by human immunodeficiency virus (HIV) [4-6].
In the US, the Multicenter AIDS Cohort study was conducted 
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creasing, the number of HIV-infected patients has increased 4 
times since 2000 in Korea, and over 1,000 newly infected patients 
have emerged every year since 2013 [14,15]. Most domestic studies 
on HIV/AIDS have been conducted on patients from specific hos-
pitals and have focused on assessing treatment effectiveness [16,17].
The goal of this study was to understand the natural progres-
sion from AIDS onset until death, in the early period of HIV in-
fection in Korean patients with HIV/AIDS who exhibit different 
epidemiological characteristics from foreigners. Additionally, to 
develop a management and treatment guideline for HIV/AIDS by 
investigating the epidemiological and clinical characteristics of 
these patients along with the identifying the factors that influence 
these characteristics. We started with the Korea HIV/AIDS Co-
hort Study (KoCosHIV), in which 15 medical institutions that 
have been treating patients with HIV/AIDS across the country 
since 2006 participated. A cohort of 1,438 patients has been estab-
lished, and the patients were repeatedly surveyed.
MATERIALS AND METHODS
Participating hospitals
A total of 21 hospitals participated in the KoCosHIV, from De-
cember 2006 to December 2016. Of these, 15 mid-, and large-
scale general hospitals currently operate across six cities (2018).
This study was conducted by a research director, researchers 
on high-risk heterosexual and homosexual men in 1983, to un-
derstand the disease progression from HIV infection to AIDS ex-
pression and death [7]. The Amsterdam cohort study of the Neth-
erlands [8], and the Swiss HIV cohort study of Switzerland were 
subsequently performed in 1984 and 1988, respectively [9]. The 
results of HIV/AIDS cohort studies from around the world, which 
were established in the early period after the recognition of AIDS, 
showed that the route of infection, immunological characteristics, 
characteristics of opportunistic infections, cause of death, and 
AIDS pathogenesis vary with country and race [10-12]. In 2003, 
Brazil established the HIV-Brazil Cohort and has been monitor-
ing patients with HIV across 26 health facilities [13].
According to the recent data released by the Joint United Nations 
Programme on HIV/AIDS, there were about 36.7 million adult 
survivors of HIV/AIDS, 1.8 million new persons infected by HIV/
AIDS, and one million deaths associated with AIDS in 2016 [14].
In Korea, since the first report of HIV-positive patients (one 
Korean, and one foreigner) in 1985, the cumulative number of pa-
tients with HIV has increased to 15,208 (13,584 Koreans, and 
1,624 foreigners) by 2016, over the last three decades. Of the 
13,584 Koreans infected, 12,606 (92.8%) were men and 978 (7.2%) 
were women; the ratio of HIV-infected men is markedly higher. 
The cumulative mortality rate is 15.8%, with 2,134 mortalities of 
the 13,584 patients, 11,439 survivors of HIV/AIDS in 2016.
Although the number of newly infected patients has been de-
Figure 1. Schematic flow chart of Korea HIV/AIDS Cohort Study organization. PI, principal investigator; IRB, institutional review board; CRF, 
case report form; SOP, standard operating procedures; KCDC, Korea Centers Disease Control and Prevention. 
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from three research centers, an epidemiological team, and the de-
partment of viral diseases of the Korea National Institute of 
Health. The research director was responsible for the administra-
tive tasks related to the research including conducting research, 
obtaining institutional review board (IRB) approval, and collecting 
data. The epidemiology research team was responsible for tasks 
related to data utilization, such as developing a standardized sur-
vey questionnaire and guideline, data cleansing, epidemiological 
consulting, providing and conducting statistical analyses. The Ko-
rea National Institute of Health has the rights to manage the con-
sent form and use data to keep track of the yearly research pro-
gress, assign cohort management numbers, conduct participant-
based repeated investigation, and manage biological resource 
samples (Figure 1). The administrative/clinical practice committee 
regularly met to share opinions related to the research and revised/
improved research tools and indices to make effective progress.
Subjects
HIV-infected Korean adults aged 18 years or older, who were 
confirmed as HIV positive by HIV Western blot, registered at the 
Korea Centers for Disease Control and Prevention (KCDC), had 
previous treatment experience at a participating hospital, and vol-
untarily consented to participating in this study after receiving a 
sufficient explanation of the research content, were included. This 
study is a cohort study, in which the dates of registration and re-
search termination vary among the participants. Data were collect-
ed in real time from multiple centers by the Integrative Manage-
ment System of the KCDC. The optimal date for the repeated inves-
tigation was six months after the investigation at the time of cohort 
registration. However, for participant convenience, a repeated in-
vestigation period was added from one to two months after the op-
timal date. Participants who were not surveyed for over two years 
after cohort registration were defined as “follow-up loss”. Reasons 
for ceasing participation, such as death or consented withdrawal, 
were documented in accordance with the survey format (Figure 2).
Four men were registered by December 2006, and the number 
of HIV-infected participants consistently increased and reached 
1,438 by 2016. Of the 13,584 HIV-infected Koreans in 2016, 
13,152 were adults aged 20 years or older. Therefore, about 11% of 
the HIV-infected patients who were eligible for registration par-
ticipated in this study (Table 1). Regarding the age distribution, 
there were 432 HIV-infected Koreans who were less than 20 years 
of age in 2016, and 11 of these patients participated in this study. 
About 10% of all infected Koreans between the ages of 20-40 
Figure 2. Korea HIV/AIDS Cohort Study design. HIV, human immunodeficiency virus; CRF, case report form; PBMC, peripheral blood mono-
nuclear cell.
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years and 13% of all infected Koreans who were 40 years of age or 
older participated in this study (Table 2).
Of the 1,438 participants who registered by December 31, 2016, 
over 50% were diagnosed as HIV positive after 2006. The mean 
age at cohort registration was 41.5 years, and the mean age at the 
time of diagnosis was 38.3 years. Of the Korean participants, 1.1% 
were naturalized foreigners. The immune status at the time of reg-
istration was determined by the number of CD4+ T cells and HIV 
RNA. The rates at which these two parameters were measured 
were 82.1 and 78.6%, respectively. There were 261 patients (18.2%) 
in the immunodeficiency group, with CD4+ T cell numbers less 
than 200, and 27 patients (1.9%) with HIV RNA numbers of 
500,000 or greater (Table 3). According to national reports, only 
6,192 Koreans (45.6%) underwent the CD4+ T cell test at the time 
of the report, of whom 2,387 (38.5% of all participants, or 17.6% 
of all HIV-infected Koreans) were in the immunodeficiency 
group (CD4< 200) [15].
Data management
The epidemiology research team manages data in three stages, 
to assure the data quality. First, the team educates clinical research 
nurses on standardized guidelines, before data collection. Second, 
the team performs real-time monitoring and manages the data-
base to minimize errors that can occur during the data collection 
process. Third, the team statistically reviews the limiting values, 
outliers, and missing value of data, and develops an algorithm for 
logical error derivation that can occur from a question or between 
different investigation timings. Next, the team cleanses the data 
twice, to estimate errors, and confirms the results with the corre-
sponding hospital. Furthermore, it provides a code book and a 
guideline on how to use the primitive data, to allow researchers to 
effectively use the cleansed data, and provides epidemiological 
consultation or statistical analysis when necessary.
Research ethics
All participating hospitals give consent for patient participation 
and provided test result information following IRB approval. Due to 
the nature of multi-year research projects, the study is continuously 
reviewed every year. To protect the patients’ personal information, 
each patient was assigned a cohort management number that did 
not include personal identification information, such as resident 
registration number, name, phone number, or address. When re-
ceiving data from the KCDC, the purpose of using the data and the 
date as well as destruction must be clearly stated and fulfilled. In ad-
dition, ethics education is regularly held for all researchers.
Method of investigation
Repeated and follow-up investigations
The date of registration varied among the participants, and new 
participants were recruited every year. For patients for whom the 
basic investigation was completed, repeated investigations of treat-
ment and disease were conducted every six months. For partici-
pants who did not show short-term changes, such as changes in 
marital statuses and health behaviors, the investigation was repeat-
edly conducted every 12 months. At least 1,000 participants were 
maintained every year, and research nurses performed quarterly 
Table 1. Enrollment by year: December 6, 2006-December 31, 2016
Enrollment year
Korea HIV/AIDS Cohort Study Korea HIV/AIDS patients1
Men Women Cumulative n (%) Men Women Cumulative n (%)
1985-2005 0 0 0 (0.0) 3,427 355 3,827 (28.2)
2006 4 0 4 (0.3) 687 62 4,576 (33.7)
2007 183 13 200 (13.9) 698 42 5,316 (39.1)
2008 260 19 479 (33.4) 743 54 6,113 (45.0)
2009 142 11 632 (44.1) 710 58 6,881 (50.7)
2010 220 18 870 (60.6) 723 50 7,654 (56.3)
2011 175 12 1,057 (73.5) 827 61 8,542 (62.9)
2012 110 9 1,176 (81.8) 808 60 9,410 (69.3)
2013 58 3 1,237 (86.0) 946 67 10,423 (76.7)
2014 93 1 1,331 (92.6) 1,016 65 11,504 (84.7)
2015 56 8 1,395 (97.0) 974 44 12,522 (92.2)
2016 40 3 1,438 (100.0) 1,002 60 13,584 (100.0)
1From Cho et al. HIV/AIDS notifications in Korea, 2016 [15].
Table 2. Age at enrollment: December 6, 2006-December 31, 2016
Age (yr) Korea HIV/AIDS Cohort Study
Korea HIV/AIDS 
patients1
Ratio  
(%)
<20  11 (0.01)  432 (0.03) 3
20-29  267 (0.19)  3,523 (0.26) 8
30-39  389 (0.27)  3,699 (0.27) 11
40-49  389 (0.27)  3,000 (0.22) 13
50-59  251 (0.17)  1,922 (0.14) 13
60+  131 (0.09)  1,008 (0.07) 13
Total 1,438 (100.0) 13,584 (100.0) 11
Values are presented as number (%).
1From Cho et al. HIV/AIDS notifications in Korea, 2016 [15].
Choi BY et al. : KoCosHIV: study design and baseline characteristics
www.e-epih.org    |  5
Table 3. Baseline characteristics: December 6, 2006-December 31, 2016 
Characteristics Total Men Women p-value
Total 1,438 (100.0) 1,341 (93.3) 97 (6.7)   
Age at enrollment (yr)
   Mean±SD
   Median  (IQR)
  
41.5±12.5
41 (32-50)
  
41.2±12.5
41 (32-50)
  
45.4±13.1
48 (34-55)
  
0.0011
  
Age at diagnosed HIV (yr)
   Mean±SD
   Median (IQR)
1,432/1,438 (99.6)
38.3±12.5
37 (28-46)
1,335/1,341 (99.6)
38.0±12.4
37 (28-46)
97/97 (100.0)
41.8±13.9
41 (30-53)
  
0.011
  
Area of origin
   Korean
   Foreigner
1,437/1,438 (99.9)
1,423 (98.9)
14 (1.0)
1,340/1,341 (99.9)
1,337 (99.7)
3 (0.2)
97/97 (100.0)
86 (88.7)
11 (11.3)
  
<0.0012
  
Year of HIV diagnosis
   Prior to 1990
   1990-1999
   2000-2005
   2006-2010
   2011-2012
   2013-2016
1,432/1,438 (99.6)
3 (0.2)
76 (5.3)
392 (27.3)
644 (44.8)
153 (10.6)
164 (11.4)
1,335/1,341 (99.6)
3 (0.2)
69 (5.2)
364 (27.1)
601 (44.8)
145 (10.8)
153 (11.4)
97/97 (100.0)
0 (0.0)
7 (7.2)
28 (28.9)
43 (44.3)
8 (8.3)
11 (11.3)
  
0.902
  
  
  
  
  
CD4 cell count at enrollment (cell/mm3)
   Median (IQR)
   ≥500
   350-499
   200-349
   <200
1,180/1,438 (82.1)
371 (219-532.5)
341 (23.7)
289 (20.1)
290 (20.2)
260 (18.1)
1,099/1,341 (82.0)
370 (218-526.0)
310 (23.1)
276 (20.6)
268 (19.9)
245 (18.3)
81/97 (83.5)
405 (244-594.0)
31 (32.0)
13 (13.4)
22 (22.7)
15 (15.5)
  
0.261
0.11
  
   
Viral load at enrollment (copies/mL) 
   Median (IQR)
   >500,000
   1,000-500,000
   400-1,000
   ≤400
1,130/1,438 (78.6)
75 (20-15,867)
27 (1.9)
418 (29.1)
46 (3.2)
639 (44.4)
1,052/1,341 (78.4)
75 (20-16,000)
27 (2.0)
388 (28.9)
45 (3.4)
592 (44.1)
78/97 (80.4)
75 (19-14,000)
0 (0.0)
30 (30.9)
1 (1.0)
47 (48.5)
  
0.481
0.362
  
    
Values are presented as number (%).
IQR, inter-quartile range. 
1Wilcoxon rank-sum test.
2Fisher’s exact test.
updates on survey rates. For participants who could not be repeat-
edly surveyed due to withdrawal or hospital transfer, a follow-up 
investigation using nationally reported data was used once every 
year, to investigate whether or not the participants were deceased. 
By January 2018, a total of 939 participants could be followed-up 
(excluding those for whom research was terminated).
Self-reported questionnaire, and examiner questionnaire
The participants answered a questionnaire that contained ques-
tions about basic information, health behaviors (smoking/alcohol 
use), route of infection, sociopsychological state (depression, anxie-
ty, quality of life), family history, medical history, vaccination histo-
ry, and symptoms related to HIV/AIDS during the basic investiga-
tion period. Medical history, vaccination history, and recent symp-
toms related to HIV/AIDS were investigated every six months.
Professional research nurses recorded patient treatment histories 
related to HIV/AIDS and associated opportunistic infections by 
referring to medical records and patient interviews, instead of us-
ing self-reported questionnaire surveys. The date of prescription 
and types of prescribed medications were recorded in detail. After 
the basic investigation period, all diseases that occurred after HIV 
diagnosis were recorded, in chronological order. In the repeated 
investigation, histories of diseases that occurred after the last inves-
tigation were recorded, and data were collected over time (Table 4). 
Body measurements and clinical examinations
The participants were adults aged 18 years or older, with no 
significant predicted height changes, and height was assessed in 
the basic investigation only. However, parameters that were prone 
to changes such as weight, waist circumference, and hip circum-
ference were measured every six months, in accordance with the 
guidelines. All body measurements were recorded up to the first 
decimal place.
It was recommended to record parameters that were examined 
during chest X-rays, in addition to a radiologist’s comments, and 
regularly assess these parameters every six months. However, if 
this was not possible, the assessment must be performed at least 
once per year. In a diagnostic test that injects purified protein de-
rivatives isolated from a Mycobacterium tuberculosis culture and 
examines the delayed hypersensitivity reaction caused by memo-
ry T cells, the diameter of the lower arm, vertical to the major 
axis, is measured in mm. If the result is positive, the investigation 
is not repeated; however, investigation is repeated every six 
months if the result is negative. The cervical pathological exami-
nation results were investigated and classified as normal or abnor-
mal. Although the enzyme linked immuno-spot and QuantiFER-
ON tests are not recommended for regular follow-up, they may 
be prescribed by the physician and performed every six months. 
Just like the purified protein derivatives of tuberculin skin test, 
Epidemiol Health 2018;40:e2018023
  |    www.e-epih.org  6
they are not performed again if the result is positive and per-
formed regularly if the result is negative. If a patient showed a re-
sponse during the qualitative Treponema pallidum test, the quan-
tified value was recorded. The standard unit for the immune test 
is 1 mm3 per number of cells, and the standard unit for viral load 
is copies/mL. In the patients for whom international units are 
used, these units must be converted to standard units. If no virus 
is detected, “0” was recorded. For the complete blood count test, 
only the test results were recorded using standard units. For hepa-
titis testing, if the qualitative test result was positive, we recom-
mended to record quantitative test results as well, and the test was 
not repeated. If the result was negative, the test was performed 
regularly, every six months, at the discretion of the physician. 
Some parameters were assessed only during the basic investiga-
tion. For general chemical tests, the results of blood collections 
that were performed in the fasting state were recorded. The esti-
mated glomerular filtration rate was automatically calculated, 
based on the registered values (gender, age, blood creatinine lev-
els), using the isotope dilution mass spectrometry-modification of 
diet in renal disease equation (Table 4).
Table 4. Korea HIV/AIDS Cohort Study questionnaires
Category Factors
Self-administered questionnaires
Sociodemographic status ID, gender, date of birth, race (ethnicity), marital status
Health-related lifestyle Smoking and drinking habits (smoking status, duration of smoking, drinking status, duration of drinking, etc.)
Transmission route Sexuality, infection route
Psychosocial status Beck Depression Inventory, State-Trait Anxiety Inventory, EuroQol 5 dimensions (2015-2018), World Health 
Organization quality of life-HIV (2018-)
Past disease history Past disease history (hypertension, diabetes mellitus, lipodystrophy, dyslipidemia, ischemic heart disease, 
cerebrovascular accident, peripheral vascular disease, hepatitis B, hepatitis C, cancer, TBc, etc.) 
Dietary supplement history 
(-2014)
Multivitamin, vitamin C, vitamin E, beta-carotene, calcium, iron, red ginseng, Chinese medicine, others
Vaccination Vaccination (BCG, hepatitis B, pneumococcal influenza, tetanus)
Family history Family history of disease
HIV/AIDS symptoms Acute HIV related symptoms, current HIV related symptoms
Investigator-administered questionnaires
AIDS related disease
Current & past HARRT history 
ART compliance
HARRT genotypic resistance (NRTI, NNRTI, major PI mutation)
Opportunistic infections 
Current & past TBc medical history
Current & past CMV medical history
Physical and clinical examinations
Physical examination Height (cm), weight (kg), waist circumference (cm), hip circumference (cm)
    Clinical examination Blood pressure (mmHg)
    Chest X-ray, PPD skin test, Pap smear, TBc ELISPOT and QuantiFERON, quantitative and qualitative syphilis 
lymphocyte tests, CD3, CD4, CD8
Viral load HIV RNA titer 
CBC WBC, Hb, Hct, platelets
Viral hepatitis HBsAg, Anti-HBs, Anti-HBc, Anti-HCV, Anti-HAV IgG, Anti-Hbe, HBeAg, HBV-DNA, HCV-PCR
CMV CMV IgG, CMV IgM, CMV RT PCR, CMV Ag
Blood chemistry FBS, Total-C, LDL-C, HDL-C, TG, AST, ALT, ALP, GGT, T-B, BUN, Cr, eGFR
BCG, bacillus Calmette–Guérin; HIV, human immunodeficiency virus; AIDS, acquired immune deficiency syndrome; HAART, highly active antiretroviral 
therapy; ART, antiretroviral therapy; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, pro-
tease inhibitor; CMV, cytomegalovirus; PPD, purified protein derivative; TBc, tuberculosis; WBC, white blood cell; Hb, hemoglobin; Hct, hematocrit; 
HBsAg, hepatitis B antigen; Anti-HBs, anti-hepatitis B surface antibody; Anti-HBc, anti-hepatitis B core antibody; Anti-HCV, anti-hepatitis C virus; Anti-
HAV IgG, anti-hepatitis A virus antibody immunoglobulin G; Anti-Hbe, anti-hepatitis B e-antigen; HBeAg, hepatitis B e-antigen; HBV-DNA, hepatitis 
B virus DNA detection test; HCV-PCR, hepatitis C virus-polymerase chain reaction test; CMV IgG, cytomegalovirus immunoglobulin G test; CMV IgM, 
cytomegalovirus immunoglobulin M; CMV RT PCR, cytomegalovirus real time polymerase chain reaction test; CMV Ag, cytomegalovirus antigen; FBS, 
fasting blood sugar; Total-C, total cholesterol; LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; TG, triglyceride; 
AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; GGT, gamma(γ) glutamyl transferase; T-B, total bilirubin; 
BUN, blood urea nitrogen; Cr, creatinine; eGFR, estimated glomerular filtration rate.
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Obtaining biological resources 
It was recommended to collect biological resources at the time 
of each investigation. The institution providing the resources was 
responsible for shipping and producing biological resource (pe-
ripheral blood mononuclear cells, plasma) samples. Blood was 
collected into two cell preparation tubes (8 mL each) then 
shipped and processed on the same day as the collection. For hos-
pitals in rural areas, under certain circumstances, samples were 
allowed to be shipped on the same day as the collection then pro-
cessed the next day, under certain circumstances. For sample 
preservation, samples were regularly sent to the Korea Biobank of 
the KCDC and permanently stored (Figure 2).
MAJOR FINDINGS
A total of 1,483 participants participated in the basic investiga-
tion, between December 2006 and February 2018. Nine hundred 
and eighty-nine participants (66.6%) participated in four or more 
repeated investigations. The researchers published a total of nine 
papers in journals, including three on the therapeutic effect of 
highly active antiretroviral therapy and compliance [18-20], two 
on sociopsychological factors (anxiety, depression) [21,22], and 
four on HIV-related diseases, opportunistic infections, hepatitis, 
and metabolic disorders [23-26]. Several papers on the manage-
ment of cohort data quality, epidemiological characteristics, route 
of infection, survival rates of HIV-infected patients and patients 
with AIDS, simultaneous diagnosis of tuberculosis, and charac-
teristics of proton beam therapy have been written and are being 
submitted for publication in scholarly journals.
Advantages/disadvantages
Over 1,000 newly infected patients have emerged on an annual 
basis since 2013, and the age at infection has been decreasing, 
with 33.9% of newly infected patients in 2016 found to be in their 
20’s [15]. This study is the only HIV/AIDS cohort study that has 
monitored the incidence of group 3 nationally notifiable commu-
nicable infections and the epidemiological and clinical data of pa-
tients with HIV/AIDS, requiring management measures collected 
over time. The data collected over the last 11 years until present 
(2018) may be used to establish a basis for successful research 
studies and effective policies for HIV-infected patients in Korea. 
In 2016, there were 4,004 HIV-infected patients in the 15 partici-
pating hospitals, which is equivalent to 29.5% of all Koreans with 
HIV infection. Thus, by encouraging consistent participation, 
data representativeness may be secured. In addition, these data 
can be used to study various topics since not only HIV/AIDS 
treatment, but also opportunistic infections, drug tolerance, and 
metabolic disorders were assessed in the early investigation.
However, this study may contain selection bias caused by the lack 
of active participation by the participants, due to the negative stig-
ma around HIV/AIDS and patients affected by HIV in Korea. The 
inherent limitations of multi-center cohort studies, and the fact that 
all participating hospitals were mid- and large-scale hospitals.
DATA ACCESSIBILITY
Data were distributed only among the researchers who partici-
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search centers is currently being planned. Data can be used in fu-
ture research, through a process that complies with cohort data 
distribution regulations.
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